Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial

Thread starter U.S. News
Start date Sep 17, 2025

U.S. News

Guest

Sep 17, 2025

Eli Lilly said orforglipron was better at lowering blood sugar levels than Novo Nordisk's oral semaglutide, and helped patients lose more weight.

Continue reading...

You must log in or register to reply here.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

Thread Information

Title: Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial

Prefix: N/A

Forum: USA News

Start date: Sep 17, 2025

Last reply date: Sep 17, 2025

Replies: 0

Thread Tags

Thread statistics

Created: U.S. News, Sep 17, 2025

Replies: 0

Views: 25

About Us

XenTR Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Color picker

Search